https://www.stocktitan.net/news/PRLD/prelude-therapeutics-to-participate-in-the-chardan-healthcare-8nz0ojngtk2l.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/PRLD/prelude-therapeutics-to-participate-in-the-chardan-healthcare-8nz0ojngtk2l.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/PRLD/prelude-announces-clinical-trial-collaboration-and-supply-agreement-2yzo2kjvmk7f.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/PRLD/prelude-announces-clinical-trial-collaboration-and-supply-agreement-2yzo2kjvmk7f.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/PRLD/prelude-therapeutics-to-participate-in-the-h-c-wainwright-28th-4r2t5hyxgwlk.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/PRLD/prelude-therapeutics-to-participate-in-the-h-c-wainwright-28th-4r2t5hyxgwlk.html?utm_source=stocktitan-bluesky&utm_medium=social
FDA IND Clearance - PRT13722 Phase 1 Study
FDA cleared the IND for PRT13722, a first-in-class oral KAT6A selective degrader, enabling a Phase 1 study in patients with HR+/HER2- breast cancer. Enrollment anticipated to begin in Q4 2…
https://biostock.app/symbols/PRLD
FDA IND Clearance - PRT13722 Phase 1 Study
FDA cleared the IND for PRT13722, a first-in-class oral KAT6A selective degrader, enabling a Phase 1 study in patients with HR+/HER2- breast cancer. Enrollment anticipated to begin in Q4 2…
https://biostock.app/symbols/PRLD
On September 10, 2026, Prelude Therapeutics Incorporated issued a press release announcing that the U.S. Food and Drug Administration cleared the Company to proceed with a Phase 1 study under its Investigational New Drug Application for PRT13722, a KAT6A degrader, being developed for the ...
On September 10, 2026, Prelude Therapeutics Incorporated issued a press release announcing that the U.S. Food and Drug Administration cleared the Company to proceed with a Phase 1 study under its Investigational New Drug Application for PRT13722, a KAT6A degrader, being developed for the ...
CRE: $3.91 (-33.7%)
BANL: $16.10 (+20.1%)
BAOS: $0.35 (-18.8%)
AKTX: $10.70 (+18.8%)
PRLD: $5.47 (-13.7%)
More: https://suggestionbox.live/planet-markets
CRE: $3.91 (-33.7%)
BANL: $16.10 (+20.1%)
BAOS: $0.35 (-18.8%)
AKTX: $10.70 (+18.8%)
PRLD: $5.47 (-13.7%)
More: https://suggestionbox.live/planet-markets
www.youtube.com/watch?v=PRld...
www.youtube.com/watch?v=PRld...
AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #HIVE 32.1x
2. #TE 5.7x
3. #ZETA 3.1x
4. #PRLD 2.5x
5. #RIG 2.3x
#OptionFlow #OptionsTrading #Trading
AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #HIVE 32.1x
2. #TE 5.7x
3. #ZETA 3.1x
4. #PRLD 2.5x
5. #RIG 2.3x
#OptionFlow #OptionsTrading #Trading